Genetics and the placebo effect: The placebome

Trends in Molecular Medicine

Volumn 21, Issue 5, 2015, Pages 285-294

  Hall, Kathryn T ^a   Loscalzo, Joseph ^b   Kaptchuk, Ted J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

COMT; No treatment control; Pharmacogenomics; Placebo; RCT

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; MICRORNA; MU OPIATE RECEPTOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANALGESIA; ANALGESIC ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAM; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; MALE; NOCEBO EFFECT; PERSONALIZED MEDICINE; PLACEBO EFFECT; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROMOTER REGION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TITRIMETRY; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); GENETIC VARIATION;

CLINICAL TRIALS AS TOPIC; GENETIC VARIATION; GENETICS; HUMANS; NEUROTRANSMITTER AGENTS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84929048588     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.02.009     Document Type: Review

References (100)

1. Raicek J.E., et al. Placebos in 19th century medicine: a quantitative analysis of the BMJ. BMJ 2012, 345:e8326.
2. Kaptchuk T.J. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull. Hist. Med. 1998, 72:389-433.
3. Kaptchuk T.J. Powerful placebo: the dark side of the randomised controlled trial. Lancet 1998, 351:1722-1725.
4. Atlas L.Y., Wager T.D. A meta-analysis of brain mechanisms of placebo analgesia: consistent findings and unanswered questions. Handb. Exp. Pharmacol. 2014, 225:37-69.
5. Benedetti F. Placebo and the new physiology of the doctor-patient relationship. Physiol. Rev. 2013, 93:1207-1246.
6. Benedetti F. Placebo Effects: Understanding The Mechanisms In Health And Disease 2009, Oxford University Press.
7. Finniss D.G., Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005, 114:3-6.
8. Wechsler M.E., et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N. Engl. J. Med. 2011, 365:119-126.
9. Servick K. Outsmarting the placebo effect. Science 2014, 345:1446-1447.
10. Horing B., et al. Prediction of placebo responses: a systematic review of the literature. Front. Psychol. 2014, 5:1079.
11. Kaptchuk T.J., et al. Do 'placebo responders' exist?. Contemp. Clin. Trials 2008, 29:587-595.
12. Finniss D.G., et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010, 375:686-695.
13. Levine J.D., et al. The narcotic antagonist naloxone enhances clinical pain. Nature 1978, 272:826-827.
14. Levine J.D., Gordon N.C. Influence of the method of drug administration on analgesic response. Nature 1984, 312:755-756.
15. Levine J.D., et al. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain 1981, 10:379-389.
16. Bingel U., et al. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006, 120:8-15.
17. Zubieta J.K., et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J. Neurosci. 2005, 25:7754-7762.
18. Zubieta J.K., Stohler C.S. Neurobiological mechanisms of placebo responses. Ann. N. Y. Acad. Sci. 2009, 1156:198-210.
19. Benedetti F., Amanzio M. Mechanisms of the placebo response. Pulm. Pharmacol. Ther. 2013, 26:520-523.
20. Amanzio M., Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 1999, 19:484-494.
21. Benedetti F., et al. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997, 71:135-140.
22. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996, 64:535-543.
23. Benedetti F., et al. Potentiation of placebo analgesia by proglumide. Lancet 1995, 346:1231.
24. Benedetti F., et al. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat. Med. 2011, 17:1228-1230.
25. Price D.D., et al. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 1999, 83:147-156.
26. Scott D.J., et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch. Gen. Psychiatry 2008, 65:220-231.
27. de la Fuente-Fernandez R., et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
28. Lidstone S.C., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 2010, 67:857-865.
29. Leuchter A.F., et al. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002, 159:122-129.
30. Mayberg H.S., et al. The functional neuroanatomy of the placebo effect. Am. J. Psychiatry 2002, 159:728-737.
31. Kirsch I., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5:e45.
32. Turner E.H., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 2008, 358:252-260.
33. Lachman H.M., et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
34. Bitsios P., Roussos P. Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics 2011, 12:559-566.
35. Farrell S.M., et al. COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol. Psychiatry 2012, 71:538-544.
36. Giakoumaki S.G., et al. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology 2008, 33:3058-3068.
37. Hall K.T., Kaptchuk T.J. Genetic biomarkers of placebo response: what could it mean for future trial design?. Clin. Invest. 2013, 3:311-314.
38. Hall K.T., et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE 2012, 7:e48135.
39. Hall K.T., et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34:2160-2167.
40. Hall K.T., et al. Conscientiousness is modified by genetic variation in catechol-O-methyltransferase to reduce symptom complaints in IBS patients. Brain Behav. 2015, 5:e00294.
41. Hamidovic A., et al. Catechol-O-methyltransferase val158met genotype modulates sustained attention in both the drug-free state and in response to amphetamine. Psychiatr. Genet. 2010, 20:85-92.
42. Tchivileva I.E., et al. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet. Genomics 2010, 20:239-248.
43. Tiwari A.K., et al. Analysis of 34 candidate genes in bupropion and placebo remission. Int. J. Neuropsychopharmacol. 2013, 16:771-781.
44. Weickert T.W., et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 2004, 56:677-682.
45. Meyer-Lindenberg A., et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 2005, 8:594-596.
46. Yavich L., et al. Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J. Neurosci. 2007, 27:10196-10209.
47. Sherry S.T., et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001, 29:308-311.
48. McLeod H.L., et al. Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. J. Pharmacol. Exp. Ther. 1994, 270:26-29.
49. Palmatier M.A., et al. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 1999, 46:557-567.
50. Kaptchuk T.J., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008, 336:999-1003.
51. Yu R., et al. Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Hum. Brain Mapp. 2014, 35:4583-4593.
52. Wendt L., et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS ONE 2014, 9:e107665.
53. Mickey B.J., et al. Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J. Neurosci. 2008, 28:11354-11359.
54. Hotamisligil G.S., Breakefield X.O. Human monoamine oxidase A gene determines levels of enzyme activity. Am. J. Hum. Genet. 1991, 49:383-392.
55. Leuchter A.F., et al. Monoamine oxidase a and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J. Clin. Psychopharmacol. 2009, 29:372-377.
56. Diaz J., et al. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
57. Bouthenet M.L., et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991, 564:203-219.
58. Lundstrom K., et al. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. J. Recept. Signal Transduct. Res. 1998, 18:133-150.
59. Bhathena A., et al. Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response. Transl. Psychiatry 2013, 3:e245.
60. Arias A.J., et al. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am. J. Addict. 2014, 23:288-293.
61. Altar C.A., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:11347-11351.
62. Goggi J., et al. Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res. 2002, 941:34-42.
63. Miczek K.A., et al. Escalated or suppressed cocaine reward, tegmental BDNF, and accumbal dopamine caused by episodic versus continuous social stress in rats. J. Neurosci. 2011, 31:9848-9857.
64. Krishnan V., et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 2007, 131:391-404.
65. Vaccarino V., et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol. Psychiatry 2008, 64:476-483.
66. Pecina M., et al. Valence-specific effects of BDNF Val66Met polymorphism on dopaminergic stress and reward processing in humans. J. Neurosci. 2014, 34:5874-5881.
67. Zhang Y., et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 2005, 280:32618-32624.
68. Kroslak T., et al. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J. Neurochem. 2007, 103:77-87.
69. Pecina M., et al. Effects of the mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology 2015, 40:957-965.
70. Chen A.C., et al. Variation in mu-opioid receptor gene as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort. J. Alcohol. Drug Depend. 2013, 1:101.
71. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002, 121:173-190.
72. Colloca L., et al. The role of learning in nocebo and placebo effects. Pain 2008, 136:211-218.
73. Pecina M., et al. FAAH selectively influences placebo effects. Mol. Psychiatry 2014, 19:385-391.
74. Hunter A.M., et al. A genome-wide association study of a sustained pattern of antidepressant response. J. Psychiatr. Res. 2013, 47:1157-1165.
75. Furmark T., et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J. Neurosci. 2008, 28:13066-13074.
76. Patel S.M., et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol. Motil. 2005, 17:332-340.
77. Bialecka M., et al. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenet. Genomics 2008, 18:815-821.
78. Gatt J.M., et al. Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. J. Psychiatr. Res. 2015, 60C:1-13.
79. Annerbrink K., et al. Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism 2008, 57:708-711.
80. Kanasaki K., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008, 453:1117-1121.
81. Wright B., et al. Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS ONE 2010, 5:e9673.
82. Thithapandha A., Srinoot P. Comparative inhibitory effects of vitamins on methylating enzymes. Comp. Gen. Pharmacol. 1972, 3:139-144.
83. Silverman E.K., Loscalzo J. Developing new drug treatments in the era of network medicine. Clin. Pharmacol. Ther. 2013, 93:26-28.
84. Antman E.S., et al. Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 4:367-383.
85. Menche J., et al. Uncovering disease-disease relationships through the incomplete interactome. Science 2015, 347:1257601.
86. Vidal M., et al. Interactome networks and human disease. Cell 2011, 144:986-998.
87. Rakvag T.T., et al. Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol. Pain 2008, 4:64.
88. Rakvag T.T., et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005, 116:73-78.
89. Kaptchuk T.J., et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 2010, 5:e15591.
90. Kam-Hansen S., et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci. Transl. Med. 2014, 6:218ra5.
91. Kelley J.M., et al. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother. Psychosom. 2012, 81:312-314.
92. Hazin R., et al. Ethical, legal, and social implications of incorporating genomic information into electronic health records. Genet. Med. 2013, 15:810-816.
93. Josko D. Personalized medicine and ethics. Clin. Lab. Sci. 2014, 27:185-190.
94. Korf B.R., Rehm H.L. New approaches to molecular diagnosis. JAMA 2013, 309:1511-1521.
95. Ormond K.E., Cho M.K. Translating personalized medicine using new genetic technologies in clinical practice: the ethical issues. Per. Med. 2014, 11:211-222.
96. Burke W., et al. Essential elements of personalized medicine. Urol. Oncol. 2014, 32:193-197.
97. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005, 65(Suppl. 4):S32-S49.
98. Lee S., et al. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress. Anxiety 2004, 19:10-19.
99. Straube S., et al. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br. J. Clin. Pharmacol. 2008, 66:266-275.
100. Caspi O., Bootzin R.R. Evaluating how placebos produce change. Logical and causal traps and understanding cognitive explanatory mechanisms. Eval. Health Prof. 2002, 25:436-464.